Drug intelligence / Profile preview

RSV vaccine candidate formulation 2

Development stage: Unknown
Lead developer: Sanofi
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

RSV vaccine candidate formulation 2 is an investigational vaccine developed by Sanofi Pasteur, a Sanofi Company, designed to prevent Respiratory Syncytial Virus (RSV) infection. This vaccine candidate is formulated as a liquid frozen solution for intramuscular injection and utilizes lipid nanoparticles (LNPs) for delivery. It is currently being evaluated in clinical trials to assess its safety and immunogenicity in adult participants.

Beyond the preview

Go deeper on RSV vaccine candidate formulation 2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RSV vaccine candidate formulation 2.

Explore the full profile